- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03613805
Eversense and Dexcom G5: Efficacy and Accuracy in Type 1 Diabetic Patients
Eversense and Dexcom G5 Comparison in Real Life: a Randomized Crossover Trial in Type 1 Diabetic Patients to Evaluate Differences in Accuracy, Efficacy and Quality of Life
Continuous Glucose Monitoring (CGM) systems improve glycaemic control in type 1 diabetic patients but they have different characteristics that could influence patients' quality of life and glycaemic control.
In this randomized cross over study investigators will compare 2 different CGM systems: Eversense implantable sensor (Senseonics, Germantown, MD, USA) and the standard transcutaneous sensor Dexcom G5 (Dexcom, San Diego, CA, USA). Investigators will evaluate sensors' accuracy, impact on quality of life and efficacy in optimizing glycaemic control.
The investigator's study's results might help clinicians choose the sensor and evaluate how sensor differences could impact glycaemic control.
연구 개요
상세 설명
Good glycaemic control in type 1 diabetic patients prevents the onset and progression of chronic complications. Continuous Glucose Monitoring (CGM) systems help patients improve glycaemic control by providing real-time glucose levels, glycaemic tendency, glycaemic swing rate and by alerting the patient when the glucose value read by the sensor reaches a predefined threshold of hyper or hypoglycaemia.
Several CGM systems are available and they have different characteristics that could influence patients' quality of life and glycaemic control.
In this randomized cross over study investigators will compare 2 different CGM systems: Eversense implantable sensor (Senseonics, Germantown, MD, USA) and the standard transcutaneous sensor Dexcom G5 (Dexcom, San Diego, CA, USA). Investigators will evaluate sensors' accuracy, impact on quality of life and efficacy in optimizing glycaemic control.
Patients will use Dexcom G5 or Eversense for three months, respectively, in a randomized order. Accuracy will be evaluated comparing sensors values with capillary blood glucose at home.
Quality of life will be assessed at the beginning and at the end of each three-month period through validated questionnaires to underline differences in different sensors use.
Time spent in target (70-180 mg/dl), in hypoglycamiea and hyperglycemia will be evaluated with both sensors to assess differences in glycaemic control induced by different alarm system and by the presence of predictive alarms
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Padova, 이탈리아
- University of Padova
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male and female participants of at least 18 years of age
- Diagnosis of type 1 diabetes mellitus (diagnosed according to World Health Organization criteria) for at least 1 year
- Body Mass Index (BMI) <35 kg / m²
- Availability to wear study equipment and to comply with the study protocol for its entire duration
- HbA1c <10%
- Signature of informed consent before any procedure related to the study.
Exclusion Criteria:
- Pregnancy, breastfeeding, intention to undergo pregnancy or refusal to use contraceptive methods during the study period (for female subjects).
- Known allergies to skin patches or disinfectants used during the study.
- Skin lesions, irritation, redness, edema in sites where sensors can be applied, as this might interfere with sensor's placement or with the accuracy of the glycaemic value detection.
- Use of drugs that may interfere with glucose metabolism (such as steroids) unless they are chronic therapies whose dosage has remained stable over the past 3 months and is expected to remain stable during the study period.
- Use of acetaminophen or other drugs that could influence sensor accuracy
- Severe medical or psychological conditions, which, in the opinion of the medical team, may compromise patients' safety while participating in the study.
- Patients enrolled in other clinical trials.
- Known disorders of adrenal glands, pancreatic tumors or insulinoma
- Patient's inability to comply with the procedures of the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: Dexcom G5 - Eversense
Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
|
Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day.
At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
|
실험적: Eversense- Dexcom G5
Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
|
Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered. After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
device accuracy
기간: after 3 months, at the end of the study for each arm of the study
|
sensors' accuracy expressed in terms of MARD (mean absolute relative difference) versus capillary blood glucose in different glycaemic ranges
|
after 3 months, at the end of the study for each arm of the study
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Time spent in target
기간: after 3 months, at the end of the study for each arm of the study
|
% Time spent in target (70-180 mg/dl) using each sensor to evaluate sensor efficacy
|
after 3 months, at the end of the study for each arm of the study
|
HbA1c
기간: after 3 months, at the end of the study for each arm of the study
|
HbA1c changes using different sensors, to evaluate sensor efficacy
|
after 3 months, at the end of the study for each arm of the study
|
failure
기간: after 3 months, at the end of the study for each arm of the study
|
% Sensors' failure rate to evaluate sensor duration
|
after 3 months, at the end of the study for each arm of the study
|
Adverse events
기간: after 3 months, at the end of the study for each arm of the study
|
Adverse events (skin reactions, haematomas)
|
after 3 months, at the end of the study for each arm of the study
|
changes in quality of life
기간: after 3 months, at the end of the study for each arm of the study
|
DTSQ questionnaire
|
after 3 months, at the end of the study for each arm of the study
|
changes in fear of hypoglycaemia
기간: after 3 months, at the end of the study for each arm of the study
|
HFSII questionnaire
|
after 3 months, at the end of the study for each arm of the study
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
Dexcom G5-Eversense에 대한 임상 시험
-
Imperial College London완전한제1형 당뇨병 | 저혈당증을 동반한 제1형 당뇨병 | 저혈당에 대한 인식 장애
-
Science Consulting in DiabetesDexCom, Inc. a Delaware corporation, USA; Institut für Diabetes-Technologie Forschungs-...완전한
-
Jessa Hospital완전한
-
Charles University, Czech Republic알려지지 않은
-
Senseonics, Inc.모집하지 않고 적극적으로